金陵药业股份有限公司 关于限制性股票回购注销完成的公告

Core Viewpoint - The company has completed the repurchase and cancellation of 1,784,100 restricted stocks, which accounts for 0.29% of the total share capital prior to the repurchase, with a total repurchase amount of RMB 6,075,789 [2][3][18] Group 1: Repurchase Details - The repurchase involved 78 individuals and was executed due to the departure of one incentive object who no longer met the criteria of the incentive plan [2][9] - The repurchase price for the initially granted restricted stocks was adjusted from RMB 3.69 per share to RMB 3.29 per share, and for the reserved stocks from RMB 4.59 per share to RMB 4.29 per share [2][14] - After the cancellation, the company's total share capital changed from 623,708,628 shares to 621,924,528 shares [3][16] Group 2: Performance and Compliance - The company did not meet the performance assessment targets set for the incentive plan, leading to the repurchase of 155,100 shares from 61 incentive objects and 20,610 shares from 16 reserved incentive objects [10][11] - The repurchase was conducted in accordance with the regulations of the incentive plan and relevant laws, ensuring compliance with corporate governance [16][18] Group 3: Financial Impact - The repurchase and cancellation of restricted stocks are not expected to have a substantial impact on the company's financial status or operational results [18] - The company's equity structure remains compliant with listing requirements, and there will be no change in control for the major shareholders [18]